Cadila receives USFDA approval for Ambrisentan

Zydus Cadila has received final USFDA approval to market Ambrisentan tablets in in strengths of 5 mg and 10 mg in the American market. The drug is prescribed to treat high blood pressure in the lungs. The product would be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. According to market estimates, sales of Ambrisentan tablets USP in the US market stood at $943 million (about Rs 6,500 crore) last year.

Company Profile : Cadila Healthcare Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.